Product Details
Product Name:
BPR1K871 |
CAS No.:
2443767-35-7 |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | BPR1K871 |
Description | BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively. |
In vitro | BPR1K871 demonstrates strong anti-proliferative effects on MOLM-13 and MV4-11 AML cells, achieving an EC50 of approximately 5 nM [1]. |
In vivo | BPR1K871, a multi-kinase inhibitor, is utilized for the treatment of acute myeloid leukemia (AML) and solid tumors [1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 125 mg/mL (237.62 mM), Sonication is recommended.
|
Keywords | BPR1K871 | DBPR-114 | DBPR 114 | BPR1K 871 | BPR1K-871 | BPR-1K871 |
Inhibitors Related | UNC2025 | Gilteritinib | Fedratinib | Nintedanib | Sunitinib | Sunitinib Malate | Sorafenib | Tandutinib | Pexidartinib | KW-2449 | Sorafenib tosylate | SGI-1776 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:60107-04-2
$0.00 / 5mg
-
-
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |